ABILIFY (Aripiprazole) drug was developed by two companies: Otsuka Pharmaceutical Co., Ltd and Bristol-Myers Squibb Company. In 2004 Abilify medicine was approved in for treating schizophrenia disease and in 2008 it was ratified as medicine for bipolar disorder.
It has been known today that the U.S. Food and Drug Administration (FDA) [...]
Abilify drug was generally approved in 2004 for treating schizophrenia disease and this medicine was supposed to be used in treating bipolar disorder. Indeed, on April 8, 2008, the European Commission allowed Abilify medication (Aripiprazole) to be marketed for patients with Bipolar I Disorder.
Such kind of disease as Bipolar I Disorder contains [...]
Abilify antipsychotic medicine was introduced in 2002 as the first and only dopamine partial agonist. It is generally prescribed for the treatment of schizophrenia disease and acute manic and mixed episodes associated with bipolar disorder.
It has been known today that the US Food and Drug Administration (FDA) approved an oral [...]
Abilify (Aripiprazole) is considered to be an effective antipsychotic medication for treating schizophrenia disease and Bipolar I Disorder. The drug is developed by two partnered companies: Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company.
They announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) [...]
Taro Iwamoto, Ph.D., Chief Executive Officer, President and Chief Operating Officer, Otsuka Pharmaceutical Development and Commercialization, Inc. stated that they are very pleased to receive expanded indications on the use of Abilify (Aripiprazole) in pediatric patients (aged 10-17) and adolescents.
In fact, The FDA first approved ABILIFY antipsychotic medicine for the treatment of [...]
